Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Eric L. Simpson, Seth Forman, Jonathan I. Silverberg, et al.
Journal of the American Academy of Dermatology (2021) Vol. 85, Iss. 1, pp. 62-70
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

JAK inhibitors in the treatment of atopic dermatitis
Raj Chovatiya, Amy S. Paller
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 4, pp. 927-940
Open Access | Times Cited: 225
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 190
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
I‐Hsin Huang, Yi‐Teng Hung, Po‐Chien Wu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 132
Systemic Immunomodulatory Treatments for Atopic Dermatitis
Aaron M. Drucker, Deanna E. Morra, David Prieto‐Merino, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 5, pp. 523-523
Open Access | Times Cited: 114
Targeted Immunotherapy for Autoimmune Disease
Seung Min Jung, Wan‐Uk Kim
Immune Network (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 107
Novel insights into atopic dermatitis
Charles F. Schuler, Allison C. Billi, Emanual Maverakis, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 5, pp. 1145-1154
Open Access | Times Cited: 107
The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment
Paola Facheris, Jane Jeffery, Ester Del Duca, et al.
Cellular and Molecular Immunology (2023) Vol. 20, Iss. 5, pp. 448-474
Open Access | Times Cited: 104
American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults
Dawn Marie R. Davis, Aaron M. Drucker, Ali Alikhan, et al.
Journal of the American Academy of Dermatology (2022) Vol. 86, Iss. 6, pp. 1335-1336.e18
Open Access | Times Cited: 96
Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
Huiying Wan, Haiping Jia, Tian Xia, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 9
Open Access | Times Cited: 73
Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies
Dawn Marie R. Davis, Aaron M. Drucker, Ali Alikhan, et al.
Journal of the American Academy of Dermatology (2023) Vol. 90, Iss. 2, pp. e43-e56
Closed Access | Times Cited: 67
Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
Alexandro Chu, Melanie Wong, Daniel Rayner, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 152, Iss. 6, pp. 1470-1492
Open Access | Times Cited: 54
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
Michael Bonelli, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 2, pp. 139-160
Open Access | Times Cited: 46
Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)
Antonio Torrelo, Barbara Rewerska, María Laura Galimberti, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 1, pp. 23-32
Open Access | Times Cited: 44
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 44
Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors
Richard W. Kim, Megan Lam, Katrina Abuabara, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 179-193
Closed Access | Times Cited: 18
Recent Advancements in the Atopic Dermatitis Mechanism
Maria Savva, Nikolaos G. Papadopoulos, Stamatios Gregoriou, et al.
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 2
Open Access | Times Cited: 16
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results
Jonathan I. Silverberg, Marjolein de Bruin‐Weller, Thomas Bieber, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 149, Iss. 3, pp. 977-987.e14
Open Access | Times Cited: 92
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4)
Thomas Bieber, Kristian Reich, C. Paul, et al.
British Journal of Dermatology (2022) Vol. 187, Iss. 3, pp. 338-352
Open Access | Times Cited: 53
The JAK/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review
Aikaterini Tsiogka, Maria Kyriazopoulou, George Kontochristopoulos, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 15, pp. 4431-4431
Open Access | Times Cited: 52
Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis
Jonathan I. Silverberg, Hwanhee Hong, Jacob P. Thyssen, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 5, pp. 1181-1196
Open Access | Times Cited: 44
Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors
Tai‐Li Chen, Ling-Ling Lee, Huei‐Kai Huang, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 11, pp. 1254-1254
Open Access | Times Cited: 41
Oral Janus kinase inhibitors for atopic dermatitis
Daniela Mikhaylov, Benjamin Ungar, Yael Renert‐Yuval, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 130, Iss. 5, pp. 577-592
Open Access | Times Cited: 35
Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments
Karolina Makowska, Joanna Nowaczyk, Leszek Blicharz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 1, pp. 781-781
Open Access | Times Cited: 33
The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta‐analysis of randomized controlled trials
Sanghyuk Yoon, Kihun Kim, Kihyuk Shin, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1, pp. 52-61
Closed Access | Times Cited: 32
Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases
Jenne P. Ingrassia, Muhammad Haisum Maqsood, Joel M. Gelfand, et al.
JAMA Dermatology (2023) Vol. 160, Iss. 1, pp. 28-28
Closed Access | Times Cited: 30
Page 1 - Next Page

Scroll to top